Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

Contact Us

Search

siRNA

Cell_Gene_Therapy

Cell and Gene Therapy Today—November 20, 2025

This weekly Cell & Gene Therapy update spans regulatory actions, durable…

ASGCT 2025 PREVIEW: Key Cell and Gene Therapy Highlights to Watch

ASGCT 2025 at a glance Count down to ASGCT 2025 with LucidQuest’s brief…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing
Public Health 2025 Review: Prevention Under Pressure and Signals Too Loud to Ignore
Lucid Diligence Brief: DP Technology Series C for AI-for-Science initiative
Cardiovascular 2025 Review: From late rescue to earlier, smarter intervention
Rare Disease 2025 Preview: From Orphan Innovation to a System-Level Stress Test

Tags

510(k) Aculys Pharma AI in drug discovery Alzheimer’s blood test Arcutis Arialys Biktarvy CAR T cell therapy Chiesi CMC risk CNSide CSF assay cytomegalovirus DB-OTO DELIVER Drug discovery AI Efpeglenatide Efsubaglutide Alfa Etana Evaxion FKRP GM1 gangliosidosis HTA IAS 2025 licensing deals MD Codes mesothelin OPKO ovarian cancer research PCSK9 inhibitor Pediatric-onset MS PureTech Health Qilu Pharmaceutical Quoin Rectal cancer Ribociclib Robotic microsurgery Soligenix TB integration TCR therapy TnpB transcatheter implant ublituximab-xiiy UTOpia bioartificial liver Whitehawk Therapeutics Yashoda

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing
Public Health 2025 Review: Prevention Under Pressure and Signals Too Loud to Ignore
Lucid Diligence Brief: DP Technology Series C for AI-for-Science initiative
Cardiovascular 2025 Review: From late rescue to earlier, smarter intervention
Rare Disease 2025 Preview: From Orphan Innovation to a System-Level Stress Test

TAGS

510(k) Aculys Pharma AI in drug discovery Alzheimer’s blood test Arcutis Arialys Biktarvy CAR T cell therapy Chiesi CMC risk CNSide CSF assay cytomegalovirus DB-OTO DELIVER Drug discovery AI Efpeglenatide Efsubaglutide Alfa Etana Evaxion FKRP GM1 gangliosidosis HTA IAS 2025 licensing deals MD Codes mesothelin OPKO ovarian cancer research PCSK9 inhibitor Pediatric-onset MS PureTech Health Qilu Pharmaceutical Quoin Rectal cancer Ribociclib Robotic microsurgery Soligenix TB integration TCR therapy TnpB transcatheter implant ublituximab-xiiy UTOpia bioartificial liver Whitehawk Therapeutics Yashoda

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy